Blue Light Cystoscopy (BLC™) with Cysview® is included in U.S. and international industry guidelines. These key industry organizations acknowledge the clinical value of this cutting-edge drug-device technology.
AUA/SUO NMIBC Guideline 20161
The American Urological Association and the Society of Urologic Oncology included this statement in their 2016 guideline.
#30. In a patient with NMIBC, a clinician should offer blue light cystoscopy at the time of TURBT, if available, to increase detection and decrease recurrence. (Moderate Recommendation; Evidence Strength: Grade B)
- At the time of resection of suspected bladder cancer, a clinician should perform a thorough cystoscopic examination of a patient’s entire urethra and bladder that evaluates and documents tumor size, location, configuration, number, and mucosal abnormalities. (Clinical Principle)
- At initial diagnosis of a patient with bladder cancer, a clinician should perform complete visual resection of the bladder tumor(s), when technically feasible. (Clinical Principle)
- A clinician should perform upper urinary tract imaging as a component of the initial evaluation of a patient with bladder cancer. (Clinical Principle)
- In a patient with a history of NMIBC with normal cystoscopy and positive cytology, a clinician should consider prostatic urethral biopsies and upper tract imaging, as well as enhanced cystoscopic techniques (blue light cystoscopy, when available), ureteroscopy, or random bladder biopsies. (Expert Opinion)
- At the time of each occurrence/recurrence, a clinician should assign a clinical stage and classify a patient accordingly as “low-,” “intermediate-,” or “high-risk.” (Moderate Recommendation; Evidence Strength: Grade C)
|AUA Risk Stratification for Non-Muscle Invasive Bladder Cancer|
|Low Risk||Intermediate Risk||High Risk|
|LGa solitary Ta ≤ 3cm||Recurrence within 1 year, LG Ta||HG T1|
|PUNLMPb||Solitary LG Ta > 3cm||Any recurrent, HG Ta|
|LG Ta, multifocal||HG Ta, >3cm (or multifocal)|
|HGc Ta, ≤ 3cm||Any CISd|
|LG T1||Any BCG failure in HG patient|
|Any variant histology|
|Any HG prostatic urethral involvement|
|aLG = low grade; bPUNLMP = papillary urothelial neoplasm of low malignant potential;
cHG = high grade; dCIS=carcinoma in situ; eLVI = lymphovascular invasion
National Comprehensive Cancer Network (NCCN) 20192
The NCCN guidelines state in the Principles of Surgical Management section for TURBT, “enhanced (blue light…) cystoscopy may be useful in identifying lesions not visible using white light cystoscopy.”
Blue light cystoscopy with Cysview may be helpful in identifying lesions not visible using white light cystoscopy
1 American Urological Association. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. American Urological Association. 2016.
2 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines-Bladder Cancer. December 2018; Version 1. 2019. Accessed January 25, 2019.